A share price of Haemonetics Corp [HAE] is currently trading at $78.79, up 4.89%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HAE shares have gain 7.21% over the last week, with a monthly amount glided 53.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Haemonetics Corp [NYSE: HAE] stock has seen the most recent analyst activity on August 11, 2025, when Raymond James downgraded its rating to an Outperform but kept the price target unchanged to $78 for it. Previously, Barrington Research reaffirmed its Outperform rating on August 08, 2025, and dropped its price target to $86. On August 08, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $62 on the stock. Citigroup upgraded its rating to a Buy but stick to its price target of $90 on July 09, 2025. Robert W. Baird initiated its recommendation with an Outperform and recommended $87 as its price target on June 26, 2025. BofA Securities downgraded its rating to Underperform for this stock on February 07, 2025, and downed its price target to $68. In a note dated December 06, 2024, JP Morgan initiated an Overweight rating and provided a target price of $116 on this stock.
Haemonetics Corp experienced fluctuations in its stock price throughout the past year between $47.31 and $89.69. Currently, Wall Street analysts expect the stock to reach $82 within the next 12 months. Haemonetics Corp [NYSE: HAE] shares were valued at $78.79 at the most recent close of the market. An investor can expect a potential return of 4.07% based on the average HAE price forecast.
Analyzing the HAE fundamentals
Trailing Twelve Months sales for Haemonetics Corp [NYSE:HAE] were 1.33B which represents -5.27% decline. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.19 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 76.47 points at the first support level, and at 74.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 80.26, and for the 2nd resistance point, it is at 81.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Haemonetics Corp [NYSE:HAE] is 1.64. Further, the Quick Ratio stands at 1.03, while the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 2.78, the price to book ratio is 4.34 and price to earnings (TTM) ratio is 22.99.
Transactions by insiders
Recent insider trading involved KROLL MARK W, Director, that happened on Nov 10 ’25 when 1400.0 shares were purchased. Former Officer, Llorens Josep completed a deal on Jun 26 ’25 to buy 18630.0 shares. Meanwhile, Former Officer Strong Stewart W bought 708.0 shares on Jun 12 ’25.
